Multi-center retrospective study on efficacy and safety of new-generation microwave ablation in patients with hepatocellular carcinoma

Multi-center retrospective study on efficacy and safety of new-generation microwave ablation in patients with hepatocellular carcinoma - Multi-center retrospective study on efficacy and safety of new-generation MWA in patients with HCC

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000052612

Enrollment

2500

Registered

2023-10-26

Start date

2023-10-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with hepatocellular carcinoma who underwent new-generation microwave ablation in participating institution will be included.

Exclusion criteria

Exclusion criteria: Patients under the age of 20.

Design outcomes

Primary

Measure	Time frame
The primary endpoint for the analysis on overall treatments is the incidence of complications classified according to the Clavien-Dindo classification. The primary endpoint for the analysis on the patients who underwent microwave ablation as first-line treatment is the duration of local control.	—

Secondary

Measure	Time frame
The secondary endpoint for the analysis on overall treatments are the target lesion response based on the Modified RECIST from contrast-enhanced CT/MRI (short-term therapeutic effects). Additionally, the number of treatments required to achieve CR (complete response) and the duration of ablation will be analyzed. Furthermore, a stratified analysis will be conducted based on patient background factors for each outcome. The secondary endpoint for the analysis on the patients who underwent microwave ablation as first-line treatment are the periods of overall survival and recurrence-free survival. Furthermore, a stratified analysis will be conducted based on patient background factors for each outcome.	—

Measure

Time frame

The secondary endpoint for the analysis on overall treatments are the target lesion response based on the Modified RECIST from contrast-enhanced CT/MRI (short-term therapeutic effects). Additionally, the number of treatments required to achieve CR (complete response) and the duration of ablation will be analyzed. Furthermore, a stratified analysis will be conducted based on patient background factors for each outcome. The secondary endpoint for the analysis on the patients who underwent microwave ablation as first-line treatment are the periods of overall survival and recurrence-free survival. Furthermore, a stratified analysis will be conducted based on patient background factors for each outcome.

—

Countries

Japan

Contacts

Public ContactNobuhito Taniki

Keio University Department of Gastroenterology and Hepatology

nobuhitotaniki@keio.jp03-3353-1211

Outcome results